๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX ยท Real-Time Price ยท USD
6.65
+0.95 (16.67%)
Nov 18, 2026, 4:00 PM EST - Market closed

Akari Therapeutics, Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-16.14-12.1-16.65-16.81-23.09-17.21
Net Income
-29.4-17.3-19.79-10.01-17.75-17.42
Earnings Per Share
-15.29-20.55-66.28-81.79-227.41-324.77
EPS Growth
------

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
5.745.22.63.8513.259.36
Total Debt
-0.753.26---
Net Cash (Debt)
5.744.45-0.663.8513.259.36
Net Cash Growth
1464.85%---70.98%41.54%-33.40%
Net Cash Per Share
2.995.29-2.2131.42169.78174.48

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-12.86-10.57-12.55-16.43-21.5-18.85
Capital Expenditures
------
Free Cash Flow
-12.86-10.57-12.55-16.43-21.5-18.85
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.